Improved tumor control through circadian clock induction by seliciclib, a cyclin-dependent kinase inhibitor

Cancer Research

Volumn 66, Issue 22, 2006, Pages 10720-10728

  Iurisci, Ida ^a,b   Filipski, Elisabeth ^a,b   Reinhardt, Jens ^d   Bach, Stéphane ^d   Gianella Borradori, Athos ^e   Iacobelli, Stefano ^c   Meijer, Laurent ^d   Lévi, Francis ^a,f  

^a HÔPITAL PAUL BROUSSE   (France)

^b UNIVERSITÉ PARIS SACLAY   (France)

^c UNIVERSITY OF CHIETI   (Italy)

^d STATION BIOLOGIQUE   (France)

^e CYCLACEL LTD   (United Kingdom)

^f INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CASEIN KINASE IEPSILON; CELL PROTEIN; CYCLIN B1; CYCLIN DEPENDENT KINASE 1; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 7; CYCLIN DEPENDENT KINASE 9; CYCLIN DEPENDENT KINASE INHIBITOR; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MYC PROTEIN; PER2 PROTEIN; PROTEIN BMAL1; PROTEIN REV ERBALPHA; PROTEIN WEE1; REV PROTEIN; ROSCOVITINE;

AFFINITY CHROMATOGRAPHY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOLOGICAL RHYTHM; CANCER CONTROL; CANCER INHIBITION; CELL CYCLE; CIRCADIAN RHYTHM; CONTROLLED STUDY; DOSE RESPONSE; DRUG MECHANISM; DRUG TOLERABILITY; GENE EXPRESSION; MALE; MOUSE; NONHUMAN; OSTEOSARCOMA; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR GROWTH;

EID: 33845317656     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-2086     Document Type: Article

References (49)

1. Schernhammer ES, Laden F, Speizer FE, et al. Rotating night shifts and risk of breast cancer in women participating in the Nurses' Health Study. J Natl Cancer Inst 2001;93:1563-8.
2. Schernhammer ES, Laden F, Speizer FE, et al. Night-shift work and risk of colorectal cancer in the nurses' health study. J Natl Cancer Inst 2003;95:825-8.
3. Megdal SP, Kroenke CH, Laden F, Pukkala E, Schernhammer ES. Night work and breast cancer risk: a systematic review and meta-analysis. Eur J Cancer 2005;41:2023-32.
4. Mormont MC, Waterhouse J, Bleuzen P, et al. Marked 24-h rest/activity rhythms are associated with better quality of life, better response, and longer survival in patients with metastatic colorectal cancer and good performance status. Clin Cancer Res 2000;6:3038-45.
5. Sephton SE, Sapolsky RM, Kraemer HC, Spiegel D. Diurnal cortisol rhythm as a predictor of breast cancer survival. J Natl Cancer Inst 2000;92:994-1000.
6. Hastings MH, Reddy AB, Maywood ES. A clockwork web: circadian timing in brain and periphery, in health and disease. Nat Rev Neurosci 2003;4:649-61.
7. Grundschober C, Delaunay F, Puhlhofer A, et al. Circadian regulation of diverse gene products revealed by mRNA expression profiling of synchronized fibroblasts. J Biol Chem 2001;276:46751-8.
8. Fu L, Lee CC. The circadian clock: pacemaker and tumour suppressor. Nat Rev Cancer 2003;3:350-61.
9. Preitner N, Damiola F, Lopez-Molina L, et al. The orphan nuclear receptor REV-ERBα controls circadian transcription within the positive limb of the mammalian circadian oscillator. Cell 2002;110:231-60.
10. Filipski E, Delaunay F, King VM, et al. Effects of chronic jet lag on tumor progression in mice. Cancer Res 2004;64:7879-85.
11. Filipski E, Innominato PF, Wu MW, et al. Effects of light and food schedules on liver and tumor molecular clocks. J Natl Cancer Inst 2005;97:507-17.
12. Filipski E, King VM, Li XM, et al. Host circadian clock as a control point in tumor progression. J Natl Cancer Inst 2002;94:690-7.
13. Matsuo T, Yamaguchi S, Mitsui S, Emi A, Shimoda F, Okamura H. Control mechanism of the circadian clock for timing of cell division in vivo. Science 2003;302:255-9.
14. Fu L, Pelicano H, Liu J, Huang P, Lee CC. The circadian gene Period2 plays an important role in tumor suppression and DNA damage response in vivo. Cell 2002;111:41-50.
15. Gery S, Komatsu N, Baldjyan L, Yu A, Koo D, Koeffler HP. The circadian gene per1 plays an important role in cell growth and DNA damage control in human cancer cells. Mol Cell 2006;22:375-82.
16. Hirayama J, Cardone L, Doi M, Sassone-Corsi P. Common pathways in circadian and cell cycle clocks: light-dependent activation of Fos/AP-1 in zebrafish controls CRY-1a and WEE-1. Proc Natl Acad Sci U S A 2005;102:10194-9.
17. Meijer L, Borgne A, Mulner O, et al. Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2, and cdk5. Eur J Biochem 1997;243:527-36.
18. Knockaert M, Greengard P, Meijer L. Pharmacological inhibitors of cyclin-dependent kinases. Trends Pharmacol Sci 2002;23:417-25.
19. Fabian MA, Biggs WH, Treiber DK, et al. A small molecule-kinase interaction map for clinical kinase inhibitors. Nat Biotechnol 2005;3:329-36.
20. Bach S, Knockaert M, Reinhardt J, et al. Roscovitine targets, protein kinases, and pyridoxal kinase. J Biol Chem 2005;280:31208-19.
21. Xu Y, Padiath QS, Shapiro RE, et al. Functional consequences of a CKIδ mutation causing familial advanced sleep syndrome. Nature 2005;434:640-4.
22. Toh KL, Jones CR, He Y, et al. An hPer2 phosphorylation site mutation in familial advanced sleep phase syndrome. Science 2001;291:1040-3.
23. Li XM, Kanekal S, Crépin D, et al. Circadian pharmacology of L-alanosine (SDX-102) in mice. Mol Cancer Ther 2006;5:337-46.
24. Tang L, Li MH, Cao P, et al. Crystal structure of pyridoxal kinase in complex with roscovitine and derivatives. J Biol Chem 2005;280:31220-9.
25. Shapiro GI. Cyclin-dependent kinase pathways as targets for cancer treatment. J Clin Oncol 2006;24:1770-83.
26. Meijer L, Raymond E. Roscovitine and other purines as kinase inhibitors. From starfish oocytes to clinical trials. Acc Chem Res 2003;36:417-25.
27. McClue SJ, Blake D, Clarke R, et al. In vitro and in vivo antitumor properties of the cyclin dependent kinase inhibitor CYC202 (R-roscovitine). Int J Cancer 2002;102:463-8.
28. Byrd JC, Lin TS, Dalton JT, et al. Flavopiridol administered as a pharmacologically-derived schedule demonstrates marked clinical activity in refractory, genetically high risk, chronic lymphocytic leukemia (CLL). Blood (ASH Annu Meet Abstr) 2004;104:341.
29. Granda TG, Liu XH, Cermakian N, et al. Circadian regulation of cell cycle and apoptosis proteins in mouse bone marrow and tumour. FASEB J 2005;19:304-6.
30. Alvi AJ, Austen B, Weston VJ, et al. A novel CDK inhibitor, CYC202 (R-roscovitine), overcomes the defect in p53-dependent apoptosis in B-CLL by down-regulation of genes involved in transcription regulation and survival. Blood 2005;105:4484-91.
31. Fisher RP. Secrets of a double agent: CDK7 in cell cycle control and transcription. J Cell Science 2005;118:5171-80.
32. 1/S phase transition. Nat Cell Biol 2005;7:831-6.
33. Meijer L, Bettayeb K, Galons H. Roscovitine (CYC202, Seliciclib). In: Yue E, Smith PJ, editors. Monographs on enzyme inhibitors, vol. 2. CDK inhibitors and their potential as anti-tumor agents. Boca Raton: CRC Press, Taylor & Francis; 2006, p. 187-226.
34. Granda TG, d'Attino RM, Filipski E, et al. Circadian optimisation of irinotecan and oxaliplatin efficacy in mice with Glasgow osteosarcoma. Br J Cancer 2002;86:999-1005.
35. Tampellini M, Filipski E, Liu X-H, et al. Docetaxel chronopharmacology in mice. Cancer Res 1998;58:3896-904.
36. Li XM, Tanaka K, Sun J, et al. Relevance of dosing time for the tolerability and antitumor efficacy of gemcitabine or combined with cisplatin in mice. Br J Cancer 2005;92:1684-9.
37. Granda TG, Lévi F. Tumor-based rhythms of anticancer efficacy in experimental models. Chronobiol Int 2002;19:21-41.
38. Balsalobre A, Damiola F, Schibler U. A serum shock induces circadian gene expression in mammalian tissue culture cells. Cell 1998;93:929-37.
39. Balsalobre A, Brown SA, Marcacci L, et al. Resetting of circadian time in peripheral tissues by glucocorticoid signaling. Science 2000;289:2344-7.
40. Nagoshi E, Saini C, Bauer C, Laroche T, Naef F, Schibler U. Circadian gene expression in individual fibroblasts: cell-autonomous and self-sustained oscillators pass time to daughter cells. Cell 2004;119:693-705.
41. Davidson AJ, Straume M, Block GD, et al. Daily timed meals dissociate circadian rhythms in hepatoma and healthy host liver. Int J Cancer 2006;118:1623-7.
42. Iurisci I, Filipski E, Gianella-Borradori A, et al. Molecular chronopharmacology of cyclin-dependent kinase inhibitor Seliciclib (R-Roscovitine) on mouse liver. 10th Biennial Meeting of the Society for Research on Biological Rhythms; 2006 May 21-25; Sandestin, Florida.
43. Lee C, Etchegaray J-P, Cagampang FRA, Loudon ASI, Reppert SM. Posttranslational mechanisms regulate the mammalian circadian clock. Cell 2001;107:855-67.
44. Akashi M, Tsuchiya Y, Yoshino T, Nishida E. Control of intracellular dynamics of mammalian period proteins by casein kinase Iε (CKIε) and CKIδ in cultured cells. Mol Cell Biol 2002;22:1693-703.
45. Eide EJ, Woolf MF, Kang H, et al. Control of mammalian circadian rhythm by CKIε-regulated proteasome-mediated PER2 degradation. Mol Cell Biol 2005;25:2795-807.
46. Bain J, McLauchlan H, Elliott M, Cohen P. The specificities of protein kinase inhibitors: an update. Biochem J 2003;371:199-204.
47. Krucher NA, Meijer L, Roberts MH. The cyclin-dependent kinase (cdk) inhibitors, olomucine and roscovitine, alter the expression of a molluscan circadian pacemaker. Cell Mol Neurobiol 1997;17:495-507.
48. Sankrithi N, Eskin A. Effect of cyclin-dependent kinase inhibitors on transcription and ocular circadian rhythm of Aplysia. J Neurochem 1999;72:605-13.
49. Knippschild U, Wolff S, Giamas G, et al. The role of the casein kinase 1 (CK1) family in different signaling pathways linked to cancer development. Onkologie 2005;28:508-14.